Compare · DXCM vs TCMD
DXCM vs TCMD
Side-by-side comparison of DexCom Inc. (DXCM) and Tactile Systems Technology Inc. (TCMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TCMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 49.1x TCMD ($572.9M).
- DXCM has been more active in the news (26 items in the past 4 weeks vs 2 for TCMD).
- DXCM has more recent analyst coverage (25 ratings vs 9 for TCMD).
- Company
- DexCom Inc.
- Tactile Systems Technology Inc.
- Price
- $76.86+5.52%
- $25.41+0.08%
- Market cap
- $28.11B
- $572.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 26
- 2
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Tactile Systems Technology Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest TCMD
- Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
- Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
- CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold $113,404 worth of shares (4,631 units at $24.49), decreasing direct ownership by 3% to 130,188 units (SEC Form 4)
- SEC Form 144 filed by Tactile Systems Technology Inc.
- Director Asbury Valerie L. was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Huggenberger Raymond was granted 6,521 shares, increasing direct ownership by 12% to 62,841 units (SEC Form 4)
- Director King Laura G. was granted 6,521 shares, increasing direct ownership by 34% to 25,569 units (SEC Form 4)
- Director Pearson Andrea was granted 6,521 shares, increasing direct ownership by 765% to 7,373 units (SEC Form 4)
- Director Shafer David Brent was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Volkart Carmen B was granted 6,521 shares, increasing direct ownership by 17% to 44,219 units (SEC Form 4)